Core Viewpoint - The study conducted by Professor Zhang Wenhong's team from Fudan University shows that the resistance mutation rate of the antiviral drug Marbofloxacin is extremely low in the Chinese population, addressing public concerns about its effectiveness against influenza due to potential viral mutations [2][3]. Group 1: Study Findings - The research analyzed nearly 4,000 samples from the Chinese population, including 44.6% children, confirming that the resistance mutation rate for Marbofloxacin is less than 0.05% [2]. - No significant resistance mutations, such as the international marker I38X, were detected in mainland China, aligning with the China CDC's report of a resistance rate of "0" [2]. - The study represents the largest scale investigation of drug resistance in China, providing a real-world baseline for Marbofloxacin's effectiveness [2]. Group 2: Monitoring Systems - The China CDC's monitoring focuses on large-scale resistance that could impact clinical efficacy, while the research team's study captures early, low-frequency molecular signals of resistance [3]. - The two monitoring systems are complementary; the CDC's data indicates current safety, while the research aims to ensure long-term effectiveness of antiviral drugs [3]. Group 3: Implications for Children - The study indicates that the use of Marbofloxacin in children does not increase the risk of resistance, as viral mutations are a random biological process not directly linked to patient age [4]. - Current monitoring data shows that Marbofloxacin does not induce viral mutations, and the identified mutations are part of natural variation without evidence of impacting treatment efficacy [4]. - The findings suggest that Marbofloxacin remains safe and effective for both current and future patients, regardless of previous use [4].